Kristin Brooks, Managing Editor, Contract Pharma07.20.20
Headquarters: King of Prussia, PA
twitter.com/CSLBehring
www.cslbehring.com
Headcount: 25,000
Year Established: 1970
Revenues: $8,951
Net Income: $2,117
R&D: $857
*CSL does not report annual results until 30 June, so data is estimated.
TOP SELLING DRUGS
twitter.com/CSLBehring
www.cslbehring.com
Headcount: 25,000
Year Established: 1970
Revenues: $8,951
Net Income: $2,117
R&D: $857
*CSL does not report annual results until 30 June, so data is estimated.
TOP SELLING DRUGS
| Drug | Indication | 2019 Sales | (+/-%) |
| Privigen | thrombocytopaenic purpura | $2,837 | 19% |
| Hizentra | immunoglobulin deficiency | $1,252 | 26% |
| Kcentra | haemorrhagic conditions | $690 | 12% |
| Human albumin | blood substitution, liver cirrhosis | $669 | -34% |
| Flucelvax | influenza prophylaxis | $521 | 21% |
| Humate P | haemophilia A | $469 | -4% |
| Idelvion | haemophilia B | $451 | 14% |
| Fluad | influenza prophylaxis | $340 | 13% |
| Haegarda | hereditary angioederma | $261 | 1% |
| Berinert P | hereditary angioederma | $241 | -1% |
